MARKET

PROF

PROF

Profound Med Corp
NASDAQ
6.88
-0.07
-1.01%
After Hours: 6.81 -0.07 -1.02% 16:05 03/17 EDT
OPEN
6.97
PREV CLOSE
6.95
HIGH
6.97
LOW
6.74
VOLUME
27.48K
TURNOVER
--
52 WEEK HIGH
11.42
52 WEEK LOW
5.63
MARKET CAP
206.67M
P/E (TTM)
-6.1254
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PROF last week (0310-0314)?
Weekly Report · 8h ago
Securities Fraud Investigation Into Profound Medical Corp. (PROF) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Barchart · 4d ago
Securities Fraud Investigation Into Profound Medical Corp. (PROF) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Barchart · 5d ago
Profound Medical’s Earnings Call: Optimism Amid Growth
TipRanks · 6d ago
Weekly Report: what happened at PROF last week (0303-0307)?
Weekly Report · 03/10 11:19
PROFOUND MEDICAL CORP - REVOLVING COMMITMENT MAY INCREASE TO $15 MILLION
Reuters · 03/07 21:10
PROFOUND MEDICAL CORP: ON MARCH 3, UNIT ENTERED AMENDED & RESTATED CREDIT AGREEMENT WITH CANADIAN IMPERIAL BANK OF COMMERCE
Reuters · 03/07 21:10
Lake Street Keeps Their Buy Rating on Profound Medical (PRN)
TipRanks · 03/07 13:56
More
About PROF
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Webull offers Profound Medical Corp stock information, including NASDAQ: PROF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PROF stock methods without spending real money on the virtual paper trading platform.